ResearcherMedical University of South CarolinaActive in the last 2 years

Xueliang Gao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-4834-0437; OpenAlex author ID A5032976364. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper

Papers 2

Targeting SERPINB5 and MSLN for Pancreatic Cancer Therapy. Last author DOI 10.3390/cancers18193242 ↗
CDKs Functional Analysis in Low Proliferating Early-Stage Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.26502/jbsb.5107060 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Jinghui Sun · 1 shared paper, 2026 · strength 0.30
- Paper Targeting SERPINB5 and MSLN for Pancreatic Cancer Therapy. DOI 10.3390/cancers18193242 ↗
Denis C. Guttridge D · 1 shared paper, 2026 · strength 0.30
- Paper Targeting SERPINB5 and MSLN for Pancreatic Cancer Therapy. DOI 10.3390/cancers18193242 ↗
Yu Zhou · 1 shared paper, 2023 · strength 0.17
- Paper CDKs Functional Analysis in Low Proliferating Early-Stage Pancreatic Ductal Adenocarcinoma. DOI 10.26502/jbsb.5107060 ↗
Shikai Zhu · 1 shared paper, 2023 · strength 0.17
- Paper CDKs Functional Analysis in Low Proliferating Early-Stage Pancreatic Ductal Adenocarcinoma. DOI 10.26502/jbsb.5107060 ↗
Juanjuan Ji · 1 shared paper, 2023 · strength 0.17
- Paper CDKs Functional Analysis in Low Proliferating Early-Stage Pancreatic Ductal Adenocarcinoma. DOI 10.26502/jbsb.5107060 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.